CompletedPhase 1ACTRN12605000636651
Phase 1 Study of Coxsackievirus A21 for the treatment of melanoma
Intratumoural administration of coxsackievirus A21 for the control of malignant melanoma.
Sponsor
Viralytics Ltd.
Enrollment
3 participants
Start Date
Sep 1, 2005
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and females
Inclusion Criteria1
- Stage IV melanoma (AJCC)- minimum of 2 SC metastases- failure or refusal of standard chemotherapy- ECOG score of 0 or 1- other.
Exclusion Criteria1
- Metastatic CNS disease- occular or mucosal melanoma- immunodeficiency- splenectomy- other.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A single intratumoural injection of coxsackievirus A21.
A single intratumoural injection of coxsackievirus A21.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000636651
Related Trials
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
NCT066364355 locations
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT061506649 locations
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
NCT0696100638 locations
Reducing Symptom Burden Through Physical Exercise in Melanoma Patients
NCT069850561 location
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
NCT073716633 locations